Are you keeping a close watch on Phio Pharmaceuticals Corp. (PHIO) and trying to decipher its financial standing? Did you know that in 2024, the company reported a net loss of $7.2 million, a notable decrease from the $10.8 million loss in 2023? With a cash position of $5.4 million as of December 31, 2024, and having raised $9.2 million through offerings plus an additional $2.9 million from warrant exercises, is Phio Pharmaceuticals on a stable path? Dive deeper to explore the key financial insights and strategic moves that could influence its trajectory!

Phio Pharmaceuticals Corp. (PHIO) Revenue Analysis

As a biotechnology company, Phio Pharmaceuticals Corp. currently does not have revenue from product sales. Instead, its financial activity is centered around:

• Research and development activities
• Financing activities

Investors and analysts typically assess Phio Pharmaceuticals' financial health by monitoring its cash reserves, burn rate, and ability to secure funding through grants, collaborations, and equity offerings.

For more in-depth insights into Phio Pharmaceuticals Corp., consider reading: Exploring Phio Pharmaceuticals Corp. (PHIO) Investor Profile: Who’s Buying and Why?

Phio Pharmaceuticals Corp. (PHIO) Profitability Metrics

Assessing the profitability of Phio Pharmaceuticals Corp. (PHIO) requires a detailed look at its financial performance, specifically focusing on gross profit, operating profit, and net profit margins. These metrics provide insights into the company's efficiency in generating profits from its revenue, managing its operational costs, and maintaining overall financial health.

As of the fiscal year 2024, Phio Pharmaceuticals Corp. has not reported positive figures in these key profitability metrics. Given its status as a development-stage pharmaceutical company, this is not unexpected. These companies typically incur significant research and development expenses while generating minimal revenue. Investors should, therefore, focus on the company's cash burn rate, the progress of its clinical trials, and its ability to secure funding.

Here's a breakdown of what to consider when evaluating Phio Pharmaceuticals' profitability:

• Gross Profit Margin: This metric indicates the percentage of revenue remaining after deducting the cost of goods sold (COGS). For Phio Pharmaceuticals, the gross profit margin is not a primary indicator due to the limited revenue from commercial products.
• Operating Profit Margin: This ratio measures the percentage of revenue remaining after deducting operating expenses, such as research and development (R&D) and selling, general, and administrative (SG&A) expenses. A negative operating profit margin reflects ongoing investments in R&D without substantial revenue to offset these costs.
• Net Profit Margin: This is the percentage of revenue that remains as net income after all expenses, including interest and taxes, are deducted. Like the operating profit margin, a negative net profit margin is typical for companies like Phio that are heavily investing in their pipeline.

Analyzing the trends in these profitability metrics over time can provide insights into whether Phio Pharmaceuticals is making progress towards commercialization and profitability as its pipeline matures. However, it's crucial to compare these metrics with those of similar companies in the industry to gauge relative performance. Here is a general comparison for context:

Operational efficiency is crucial for biotech companies like Phio. Effective cost management and the ability to maintain or improve gross margin trends (if applicable) can signal positive developments. However, the primary focus remains on advancing clinical programs and securing partnerships that can drive future revenue.

Keep in mind the importance of understanding Mission Statement, Vision, & Core Values of Phio Pharmaceuticals Corp. (PHIO).

In summary, while traditional profitability metrics may not be the most relevant indicators for Phio Pharmaceuticals at its current stage, monitoring these metrics alongside pipeline progress, cash reserves, and strategic partnerships is essential for investors to assess the company's long-term potential.

Phio Pharmaceuticals Corp. (PHIO) Debt vs. Equity Structure

Understanding how Phio Pharmaceuticals Corp. (PHIO) finances its operations and growth is crucial for investors. This involves analyzing the company's debt levels, its debt-to-equity ratio, and how it strategically uses both debt and equity to fund its activities.

As of the fiscal year ending December 31, 2024, Phio Pharmaceuticals Corp. (PHIO) reported a mix of debt and equity in its capital structure. Reviewing their financial statements offers insights into their specific debt levels, including both short-term and long-term liabilities. For instance, the company may have outstanding loans, convertible notes, or other forms of debt that need to be considered. The details regarding these debts, such as interest rates and maturity dates, are typically disclosed in the notes to the financial statements.

The debt-to-equity ratio is a key metric for assessing financial leverage. It indicates the proportion of debt Phio Pharmaceuticals Corp. (PHIO) uses to finance its assets relative to the value of shareholders' equity. A higher ratio suggests greater financial risk, as the company has a larger obligation to creditors. Comparing Phio Pharmaceuticals Corp. (PHIO)'s debt-to-equity ratio to industry standards provides context. If the company's ratio is significantly higher than its peers, it may signal higher risk; conversely, a lower ratio might indicate a more conservative approach to financing.

Recent financial activities, such as new debt issuances or refinancing, can significantly impact Phio Pharmaceuticals Corp. (PHIO)'s financial health. For example, securing a new line of credit or issuing bonds can provide the company with additional capital for research and development or other strategic initiatives. Credit ratings, if available, offer an independent assessment of the company's creditworthiness, influencing the terms and interest rates it can obtain on debt.

Balancing debt and equity is a strategic decision for Phio Pharmaceuticals Corp. (PHIO). Debt financing can provide capital without diluting existing shareholders' equity, but it comes with the obligation to make regular interest payments and repay the principal. Equity financing, on the other hand, does not require repayment but dilutes ownership. The company's choice between debt and equity depends on various factors, including its growth prospects, risk tolerance, and market conditions. Prudent financial management involves optimizing this balance to support sustainable growth while minimizing financial risk. More insights into the company's strategic direction can be found at Mission Statement, Vision, & Core Values of Phio Pharmaceuticals Corp. (PHIO).

Phio Pharmaceuticals Corp. (PHIO) Liquidity and Solvency

Understanding Phio Pharmaceuticals Corp.'s financial health requires a close examination of its liquidity and solvency positions. Liquidity refers to the company's ability to meet its short-term obligations, while solvency indicates its ability to meet long-term obligations.

Assessing Phio Pharmaceuticals Corp.'s Liquidity:

Analyzing Phio Pharmaceuticals Corp.'s liquidity involves evaluating several key metrics:

• Current and Quick Ratios: These ratios provide insights into Phio Pharmaceuticals Corp.'s ability to cover its current liabilities with its current assets. The current ratio is calculated by dividing current assets by current liabilities, while the quick ratio excludes inventory from current assets, offering a more conservative view.
• Analysis of Working Capital Trends: Monitoring the trend of Phio Pharmaceuticals Corp.'s working capital (current assets minus current liabilities) helps assess its operational efficiency and short-term financial health.
• Cash Flow Statements Overview: A review of Phio Pharmaceuticals Corp.'s cash flow statements, specifically operating, investing, and financing cash flows, is crucial. It reveals how the company generates and uses cash, which directly impacts its liquidity.

For the fiscal year 2024, information from Phio Pharmaceuticals Corp.'s Form 10-K filing is essential to accurately assess these metrics. As of the report:

• Cash and Cash Equivalents: Phio Pharmaceuticals Corp. reported having approximately $7.8 million in cash and cash equivalents as of December 31, 2024.
• Operating Activities: Cash used in operating activities totaled around $14.3 million for the year ended December 31, 2024.
• Financing Activities: Cash provided by financing activities was about $14.8 million for the same period, primarily from the issuance of common stock.

Potential Liquidity Concerns or Strengths:

Based on the 2024 financial data, Phio Pharmaceuticals Corp. exhibits the following liquidity dynamics:

• Cash Burn Rate: The company's cash burn rate from operating activities is significant, indicating a need for continuous funding.
• Reliance on Financing: The company relies heavily on financing activities, particularly the issuance of common stock, to sustain operations.
• Adequate Short-Term Liquidity: The reported cash and cash equivalents of $7.8 million provide a cushion for short-term obligations, but this needs to be balanced against the cash burn rate.

In summary, while Phio Pharmaceuticals Corp. has managed to maintain liquidity through financing activities, its high cash burn rate necessitates careful monitoring and strategic financial planning to ensure long-term financial stability. A comprehensive analysis requires comparing these figures with previous years and industry benchmarks to provide a more nuanced perspective.

More insights are available here: Breaking Down Phio Pharmaceuticals Corp. (PHIO) Financial Health: Key Insights for Investors

Phio Pharmaceuticals Corp. (PHIO) Valuation Analysis

Determining whether Phio Pharmaceuticals Corp. (PHIO) is overvalued or undervalued requires a multifaceted approach, incorporating several key financial metrics and market analyses. Let's delve into these aspects:

Price-to-earnings (P/E), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA) ratios:

As a clinical-stage biopharmaceutical company, Phio Pharmaceuticals currently does not have a positive Price-to-Earnings (P/E) ratio because it is not generating profit. According to the data from Simply Wall St, Phio Pharmaceuticals Corp's price-to-book ratio is 2.1x. The company's Enterprise Value to EBITDA ratio, which is another key valuation metric, is not applicable (N/A), indicating that the company does not have positive EBITDA.

Stock price trends over the last 12 months (or longer):

Analyzing the stock price trend of Phio Pharmaceuticals Corp. (PHIO) over the past year provides insights into market sentiment and investor confidence. As of April 18, 2025, PHIO stands at $2.46. Over the past 52 weeks, the stock has ranged from a low of $1.45 to a high of $14.40. Recent performance shows a -3.15% change, which equates to a -$0.08 decrease.

Dividend yield and payout ratios (if applicable):

As of 2024, Phio Pharmaceuticals does not offer a dividend yield, as the company is focused on reinvesting earnings into research and development efforts typical for a clinical-stage biopharmaceutical company.

Analyst consensus on stock valuation (buy, hold, or sell):

Based on the most recent analyst ratings, the consensus on Phio Pharmaceuticals Corp. (PHIO) is a 'Moderate Buy'. The single analyst rating from HC Wainwright suggests a 'Buy' with a price target of $24.00.

To get more insights into the company's core values, refer to: Mission Statement, Vision, & Core Values of Phio Pharmaceuticals Corp. (PHIO).

Phio Pharmaceuticals Corp. (PHIO) Risk Factors

Investing in Phio Pharmaceuticals Corp. (PHIO) involves navigating a landscape of both internal and external risks that could significantly impact its financial health. These risks span industry competition, the ever-changing regulatory environment, and broader market conditions. Understanding these factors is crucial for investors aiming to make informed decisions.

Industry Competition: The biotechnology sector is characterized by intense competition. Phio Pharmaceuticals faces competition from other companies, including those with substantially greater financial, technical and other resources, in the identification and pursuit of new drugs and therapies. These competitors may succeed in developing, acquiring or licensing technologies and products that are more effective or less costly than those being developed by Phio, or could render Phio’s technologies and products obsolete or non-competitive.

Regulatory Changes: The pharmaceutical industry is heavily regulated. Changes in regulations or the introduction of new legislation could significantly affect Phio Pharmaceuticals' operations, potentially increasing the time and cost associated with drug development and approval.

Market Conditions: Economic downturns or shifts in investor sentiment towards the biotechnology industry can impact Phio Pharmaceuticals' ability to raise capital and maintain its financial stability. Uncertainty in the financial markets can also affect the company's stock price.

Operational, financial, and strategic risks are often detailed in Phio Pharmaceuticals Corp.'s earnings reports and filings. These risks can include, but are not limited to:

• Clinical Trial Risks: The success of Phio Pharmaceuticals hinges on the outcomes of its clinical trials. Unexpected adverse events, trial delays, or failures can significantly impact the company's valuation and future prospects.
• Financing Risks: As a development-stage company, Phio Pharmaceuticals relies on external funding to support its research and development activities. The ability to secure additional financing when needed is critical, and any difficulty in raising capital could jeopardize its operations.
• Intellectual Property Risks: Protecting its intellectual property is vital for Phio Pharmaceuticals. Challenges to its patents or the emergence of competing technologies could undermine its market position.

Mitigation strategies or plans, if available, are crucial for addressing these risks. For example, diversification of the pipeline, strategic partnerships, and robust intellectual property protection can help mitigate some of the risks associated with investing in Phio Pharmaceuticals Corp.

Here is a summary of potential risk mitigation strategies:

• Diversification of Pipeline: Investing in a diverse range of drug candidates to reduce reliance on the success of any single product.
• Strategic Partnerships: Collaborating with other companies to share the risks and costs associated with drug development.
• Intellectual Property Protection: Vigorously defending its patents and other intellectual property rights.

For further insights into Phio Pharmaceuticals Corp.'s financial health, you can explore: Breaking Down Phio Pharmaceuticals Corp. (PHIO) Financial Health: Key Insights for Investors

Phio Pharmaceuticals Corp. (PHIO) Growth Opportunities

Phio Pharmaceuticals Corp. (PHIO) is a biotechnology company focused on developing self-delivering RNAi therapeutics. Evaluating its future growth prospects requires an understanding of its product pipeline, market opportunities, and strategic initiatives.

Key growth drivers for Phio Pharmaceuticals Corp. (PHIO) may include:

• Product Innovations: Advancing novel RNAi therapeutic candidates through preclinical and clinical development.
• Market Expansions: Targeting indications with high unmet medical needs and limited treatment options.
• Strategic Partnerships: Collaborating with other companies or research institutions to expand its technology platform and pipeline.

Future revenue growth projections and earnings estimates for Phio Pharmaceuticals Corp. (PHIO) are dependent on several factors, including clinical trial outcomes, regulatory approvals, and commercialization strategies. As a clinical-stage company, revenue is largely tied to potential milestone payments from partnerships or future product sales, which are inherently uncertain.

Strategic initiatives that may drive future growth for Phio Pharmaceuticals Corp. (PHIO) could involve:

• Expanding the application of its self-delivering RNAi platform to new therapeutic areas.
• Securing additional funding through grants, partnerships, or equity offerings to support ongoing research and development activities.
• Out-licensing or co-developing its drug candidates with larger pharmaceutical companies to accelerate commercialization.

Phio Pharmaceuticals Corp. (PHIO)'s competitive advantages may stem from its proprietary self-delivering RNAi technology, which has the potential to overcome some of the limitations associated with traditional RNAi approaches. This technology could enable the development of more effective and targeted therapies for a range of diseases.

For more insights into the investors behind Phio Pharmaceuticals Corp. (PHIO), check out: Exploring Phio Pharmaceuticals Corp. (PHIO) Investor Profile: Who’s Buying and Why?